American College of Rheumatology

Since August, Mallinckrodt PLC (NYSE: MNK) declined 44 percent. Barclays' Douglas Tsao slashed its price target by more than 20 percent from $130 to $100. Tsao said that it's "hard to imagine sentiment" for Mallinckrodt worsening, but noted that there are upcoming events that might help stem the...